- Your cart is empty
- Continue Shopping
KBM502 Ready-to-Use Media for NK Cell Expansion
KBM502 Ready-to-Use Media for NK Cell Expansion
Add to cart
KBM 502: Fueling the Future of NK Cell Therapy with Advanced Expansion Media
High-Yield, Serum-Free Media for Robust Human NK Cell Expansion
Drive your NK cell research forward with KBM 502, a cutting-edge cell culture media designed to maximize the expansion of human NK cells. This optimized formulation provides a serum-free environment, ensuring consistent performance and high-yield expansion for your cell therapy research.
Key Benefit of KBM 502:
- Superior NK Cell Expansion: Specifically formulated to promote robust expansion of activated human NK cells.
- Serum-Free Formulation: Eliminates the variability and potential contaminants associated with serum, ensuring consistent results.
- Defined Composition: Contains only human serum albumin, human transferrin, recombinant human insulin, and recombinant human IL-2.
- Enhanced Buffering Capacity: Maintains stable pH for optimal NK cell growth and viability.
- Contains Human IL-2: Pre-supplemented with human interleukin-2 (IL-2) to support NK cell proliferation.
Applications:
- NK Cell Therapy Research: Expand NK cells for use in adoptive cell therapies targeting cancer and other diseases.
- Immunotherapy/Immunological Studies: Investigate NK cell function, activation, and cytotoxicity.
- Drug Discovery: Screen drug candidates for their effects on NK cell activity.
Why Choose KBM 502 for Your NK Cell Research:
- High Yield: Achieve robust NK cell expansion with our optimized serum-free formulation.
- Consistent Performance: Eliminate the variability of serum and ensure reproducible results.
- User-Friendly: Easy-to-use media with convenient packaging options.
- Regulatory Support: Manufactured in compliance with relevant quality standards.
*The KBM 502 and KBM 502B media contain kanamycin sulfate as an antibiotic
Accelerate your NK cell research with KBM 502. Contact us today to learn more and request a quote.
Publications
Kohara, H., Utsugisawa, T., Sakamoto, C., Hirose, L., Ogawa, Y., Ogura, H., Sugawara, A., Liao, J., Aoki, T., Iwasaki, T., Asai, T., Doisaki, S., Okuno, Y., Muramatsu, H., Abe, T., Kurita, R., Miyamoto, S., Sakuma, T., Shiba, M., . . . Tani, K.
KLF1 mutation E325K induces cell cycle arrest in erythroid cells differentiated from congenital dyserythropoietic anemia patient-specific induced pluripotent stem cells.
Experimental Hematology, 73, 25-37.e8. (2019).
Article Snippet: “Mononuclear cells were isolated from blood samples by density gradient centrifugation using Ficoll–Paque PLUS (GE Healthcare, Little Chalfont, UK), and T lymphocytes were expanded by culture in interleukin-2 (IL-2)-containing KBM-502 medium (Kohjin Bio, Saitama, Japan)…”
Fukunaga, I., Shiga, T., Chen, C., Oe, Y., Danzaki, K., Ohta, S., Matsuoka, R., Anzai, T., Hibiya-Motegi, R., Tajima, S., Ikeda, K., Akamatsu, W., & Kamiya, K.
Generation of the induced pluripotent stem cell (hiPSC) line (JUFMDOi004-A) from a patient with hearing loss carrying GJB2 (p.V37I) mutation.
Stem Cell Research, 43, 101674. (2020).
Article Snippet: “The PBMCs were cultured for 10 days in KBM502 (Kohjin Bio).”
Arai, D., Takahashi-Shibata, M., Ukaji, T., Tsutsumi, H., Tajima, S., Nishio, S., Ishikawa, K., Akamatsu, W., Matsumoto, F., Ikeda, K., Usami, S., & Kamiya, K.
Generation of an induced pluripotent stem cell line from a late-onset, progressive high frequency hearing loss patient due to mutation in CDH23.
Stem Cell Research, 79, 103471. (2024).
Article Snippet: “On the 3rd day, the PBMCs were replated on mitomycin C (MMC)-treated mouse STO feeder cells and cultured in KBM502.“
Sawada, T., Chater, T.E., Sasagawa, Y. et al.
Developmental excitation-inhibition imbalance underlying psychoses revealed by single-cell analyses of discordant twins-derived cerebral organoids.
Mol Psychiatry 25, 2695–2711 (2020).
DOI: https://doi.org/10.1038/s41380-020-0844-z
Article Snippet: “The transfected cells were then seeded onto 100-mm dishes covered with mitomycin C-treated SNL76/7 feeder cells (ATCC, VA, USA) in KBM502 (Kohjin Bio, Saitama, Japan) supplemented with 16.7 μl/106 cells of Dynabeads Human T-Activator CD3/CD28 (Thermo Fisher Scientific, MA, USA).”
Qian, E., Uemura, M., Kobayashi, H. et al.
A human induced pluripotent stem cell model from a patient with hereditary cerebral small vessel disease carrying a heterozygous R302Q mutation in HTRA1.
Inflamm Regener 43, 23 (2023).
DOI: https://doi.org/10.1186/s41232-023-00273-7
Article Snippet: “For T lymphocytes expansion and activation, the cells were cultured for 7 days with KBM502 (Kohjin Bio, Saitama, Japan) with Dynabeads Human T-Activator CD3/CD28…”
Yamashita, K., Iwatsuki, M., Yasuda-Yoshihara, N. et al.
Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
Br J Cancer 124, 595–603 (2021).
DOI: https://doi.org/10.1038/s41416-020-01138-3
Article Snippet: “To maintain NK cell viability and activity, KBM 502 (Kohjin Bio Co., Saitama, JP) which is a medium that contains human IL-2, was used for the co-culture assays.”
Yamamoto, G., Miyabe, I., Tanaka, K. et al.
SVA retrotransposon insertion in exon of MMR genes results in aberrant RNA splicing and causes Lynch syndrome.
Eur J Hum Genet 29, 680–686 (2021).
DOI: https://doi.org/10.1038/s41431-020-00779-5
Article Snippet: “These cells were resuspended in KBM502 (KOHJIN BIO, Sakado, Japan) supplemented with 10% FBS (GE Healthcare) and penicillin–streptomycin (FUJIFILM Wako Pure Chemical, Osaka, Japan), and plated and cultured in tissue culture tubes (TPP, Trasadingen, Switzerland) at 37 °C in a 5% CO2 humidified atmosphere.”
Ukaji, T., Takahashi-Shibata, M., Arai, D., Tsutsumi, H., Tajima, S., Akamatsu, W., Matsumoto, F., Ikeda, K., Usami, S., & Kamiya, K.
Generation and characterization of a human iPSC line (JUFMDOi007-A) from a patient with Usher syndrome due to mutation in USH2A.
Stem Cell Research, 69, 103100. (2023).
Article Snippet: “The PBMCs were cultured for 7 days in KBM502 (Kohjin Bio) and reprogrammed using the Sendai virus (CytoTune-iPS 2.0 Sendai Reprogramming kit, Thermo Fisher Scientific) according to the manufacturer’s protocol.”
Fukunaga, I., Oe, Y., Danzaki, K., Ohta, S., Chen, C., Iizumi, M., Shiga, T., Matsuoka, R., Anzai, T., Hibiya-Motegi, R., Tajima, S., Ikeda, K., Akamatsu, W., & Kamiya, K.
Generation of two iPSC lines from siblings of a homozygous patient with hearing loss and a heterozygous carrier with normal hearing carrying p.G45E/Y136X mutation in GJB2.
Stem Cell Research, 53, 102290. (2021).
Article Snippet: “Two days after infection, PBMCs were transferred onto mitomycin-C treated mouse STO cells and cultured in KBM502 (Kohjin Bio).”
Kuroda, Y., Yuasa, S., Watanabe, Y., Ito, S., Egashira, T., Seki, T., Hattori, T., Ohno, S., Kodaira, M., Suzuki, T., Hashimoto, H., Okata, S., Tanaka, A., Aizawa, Y., Murata, M., Aiba, T., Makita, N., Furukawa, T., Shimizu, W., . . . Fukuda, K.
Flecainide ameliorates arrhythmogenicity through NCX flux in Andersen-Tawil syndrome-iPS cell-derived cardiomyocytes.
Biochemistry and Biophysics Reports, 9, 245–256. (2017).
Article Snippet: “After 24 h of infection, the medium was changed to fresh KBM 502 medium (KOHJIN BIO, Saitama, Japan), and the cells were collected and split at 5×104 cells into 10 cm plates pre-seeded with mouse embryonic fibroblasts (MEFs). “
Product Specifications
| Product No. | Product Name | Size | Shelf time | Storage |
|---|---|---|---|---|
| 16025015 | KBM 501 （IL-2：2810 IU/mL） | 500 mL | 8 months | 2-8℃ |
| 16025020 | KBM 502 （IL-2： 281 IU/mL） | 1000 mL | 8 months | 2-8℃ |
| 1602502B | KBM 502B（IL-2： 281 IU/mL） | 1000 mL | 8 months | 2-8℃ |
